Affordable Access

deepdyve-link
Publisher Website

A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice

Authors
  • Laczkó, Dorottya1
  • Hogan, Michael J.2
  • Toulmin, Sushila A.2
  • Hicks, Philip3, 4
  • Lederer, Katlyn3
  • Gaudette, Brian T.5
  • Castaño, Diana3, 6
  • Amanat, Fatima7, 8
  • Muramatsu, Hiromi1
  • Oguin, Thomas H. III9
  • Ojha, Amrita10
  • Zhang, Lizhou10
  • Mu, Zekun9
  • Parks, Robert9
  • Manzoni, Tomaz B.3
  • Roper, Brianne3
  • Strohmeier, Shirin7
  • Tombácz, István1
  • Arwood, Leslee9
  • Nachbagauer, Raffael7
  • And 22 more
  • 1 Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
  • 2 Division of Protective Immunity, Children’s Hospital of the University of Pennsylvania, Philadelphia, PA, USA
  • 3 Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
  • 4 School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA
  • 5 The Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
  • 6 Grupo de Inmunología Celular e Inmunogenética, Instituto de Investigaciones Médicas, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
  • 7 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • 8 Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • 9 Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA
  • 10 Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL, USA
  • 11 BioNTech RNA Pharmaceuticals, Mainz, Germany
  • 12 BIOQUAL Inc., Rockville, MD, USA
  • 13 Acuitas Therapeutics, Vancouver, BC, Canada
  • 14 Department of Pathology, Duke University Medical Center, Durham, NC, USA
Type
Published Article
Journal
Immunity
Publication Date
Jul 30, 2020
Volume
53
Issue
4
Pages
724–732
Identifiers
DOI: 10.1016/j.immuni.2020.07.019
PMID: 32783919
PMCID: PMC7392193
Source
PubMed Central
Keywords
Disciplines
  • Report
License
Unknown

Abstract

SARS-CoV-2 mRNA-based vaccines are among the most promising vaccine candidates against COVID-19. Laczkó et al. evaluate two nucleoside-modified mRNA vaccine candidates in mice and demonstrate that they induce potent T and B cell immune responses and high levels of neutralizing antibodies after administration of a single vaccine dose.

Report this publication

Statistics

Seen <100 times